News
Press ReleaseRevive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
Revive Therapeutics provides an update on its DRDC-led study evaluating Bucillamine as a potential nerve agent treatment, with final findings pending authorization.
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
Revive Therapeutics provides an update on its DRDC-led study evaluating Bucillamine as a potential nerve agent treatment, with final findings pending authorization.
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
Revive Therapeutics closes second tranche of private placement, issuing 4,352,381 units at $0.021 per unit to raise $91,400 for working capital and payables.
Revive Therapeutics Announces Extension of Proposed Private Placement
Revive Therapeutics extends its private placement offering to raise up to $650K via ~30.95M units at $0.021, each with a warrant exercisable at $0.05.
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
Revive Therapeutics closes first tranche of private placement—2.9M units raised $60.9K, settled $67.4K debt via 3.2M units; proceeds to fund operations.
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
Revive Therapeutics plans a private placement of up to 30.95M units at $0.021 generating up to $650K and settling $67.4K debt via securities issuance.